Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Niagen Bioscience ( (NAGE) ) has provided an update.
On May 6, 2026, Niagen Bioscience reported first-quarter 2026 net sales of $31.5 million, a 3% increase year over year or 5% excluding its recently divested Analytical Reference Standards and Services segment, with gross margin improving to 63.5% and net income rising to $6.3 million aided by a $4.8 million divestiture gain. The company used $1.2 million in operating cash flow, ended the quarter with $66.5 million in cash, repurchased $2.4 million of stock, and updated its full-year 2026 outlook to reflect higher sales and marketing and infrastructure spending while maintaining expectations for net sales growth and modest gross margin improvement.
Operationally, Niagen advanced its Niagen Plus platform in early 2026 with a U.S. telehealth launch for prescription at-home injections, an expanded 503B compounding network, and a cruise ship Medi-Spa clinic rollout, while also entering skincare with its Nanocloud topical product and supporting the first U.S. Pharmacopeia monograph for nicotinamide riboside chloride. The February 2026 sale of the Analytical Reference Standards and Services segment to LGC Standards further focused the business on core NAD+ science, even as operating expenses rose 26% from planned brand and R&D investments, positioning the company for broader commercial reach across premium wellness, clinical, and new category channels.
The most recent analyst rating on (NAGE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Neutral.
The score is driven primarily by improved fundamentals (profitability turnaround and a very low-leverage balance sheet) and a generally constructive earnings-call outlook despite slower 2026 growth guidance and higher planned spending. Offsetting these strengths are weak technicals (price below key moving averages with negative MACD) and a relatively high P/E with no dividend support.
To see Spark’s full report on NAGE stock, click here.
More about Niagen Bioscience
Niagen Bioscience, Inc. is a Los Angeles-based life sciences company focused on NAD+ science, centered on its Tru Niagen and Niagen brands of nicotinamide riboside-based dietary supplements, injectables, and related wellness products. The company targets consumer wellness, clinical, and emerging pharmaceutical and skincare markets through e-commerce, clinic channels, and specialized partnerships, while streamlining its portfolio around core NAD+ technologies.
Average Trading Volume: 1,151,482
Technical Sentiment Signal: Sell
Current Market Cap: $394.8M
Learn more about NAGE stock on TipRanks’ Stock Analysis page.